Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

Understanding CLL


Read More Stories
Jun 10, 2021

Chronic lymphocytic leukemia, or CLL, is a slow-growing cancer in the blood and bone marrow.1 It is the most common type of adult leukemia in the U.S.2

ESTIMATED NEW CASES OF CLL IN THE U.S. IN 20213

CLL is generally a disease that affects older adults.3

AVERAGE AGE AT DIAGNOSIS3
MAY HAVE OTHER MEDICAL CONDITIONS AT DIAGNOSIS4

In people with CLL, the leukemia starts in white blood cells called lymphocytes.1

These CLL cells multiply uncontrollably, eventually crowding out normal cells in the bone marrow and in the bloodstream.1

Sometimes, genetic changes are present in CLL cells that can make the disease more difficult to treat. Common types of genetic changes associated with poor outcomes in people with CLL include:5

Signs and symptoms of CLL vary and may take years to appear.1

Physicians may recommend a “watch and wait” or observational approach until disease progression for some people with CLL who do not show any symptoms.8

Symptoms of CLL may be seen in other conditions as well. Only a doctor will be able to tell if the symptoms are related to CLL.8

PERSISTENT WEAKNESS AND TIREDNESS
WEIGHT LOSS
SWOLLEN LYMPH NODES OR ENLARGED SPLEEN
FEVER
REPEATED INFECTIONS
BLEEDING

CLL is incurable.7

Although signs of CLL may disappear for a while after initial treatment, many people require additional treatment due to the return of cancerous cells.8

RADIATION
CHEMOTHERAPY
BONE MARROW OR STEM CELL TRANSPLANT
MONOCLONAL ANTIBODIES
OTHER TARGETED AGENTS

Targeted fixed-duration regimens are an option for people with CLL.9

Some treatment options are taken continuously until the medicine stops working, or certain side effects are observed.9

Other treatment options are fixed-duration, meaning that after a specified amount of time patients can stop taking the medicine and still experience clinical benefit.9

References

  1. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®). http://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq. Accessed March 29, 2019.
  2. Byrd J. Introduction to a Series of Reviews on Chronic Lymphocytic leukemia (CLL). Blood. June 11, 2015. DOI: 10.1182/blood-2015-06-639161.
  3. American Cancer Society. Key Statistics for Chronic Lymphocytic Leukemia. https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/key-statistics.html. Accessed June 1, 2021.
  4. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. Jan 2008;49(1):49-56.
  5. Puiggros A, Blanco G, Espinet B. Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go. BioMed Res Int. 2014. DOI: 10.1155/2014/435983.
  6. Strati P, Keating MJ, O’Brian SM, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. Aug 2014;99(8):1350-5. DOI: 10.3324/haematol.2014.104661.
  7. Dighiero G and Hamblin T. Chronic Lymphocytic Leukemia. The Lancet. 2008; 371:1017-1029.
  8. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment – for health professionals (PDQ®). http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq. Accessed March 29, 2019.
  9. Cuneo A and Foa R. Relapsed/Refractory chronic lymphocytic leukemia: chemoimmunotherapy, treatment until progression with mechanism driven agents or finite-duration therapy? Mediterranean Journal of Hematology and Infectious Disease. Feb 2019;11(1): e2019024

HEM/062316/0011(1)


Tags:

  • Hematology,
  • Follow the Science

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.